Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.

CFSAN decides on Center for Magnesium Education and Research LLC's 2016 petition requesting FDA authorize a qualified health claim about relationship between magnesium and reduced risk of high blood pressure, or hypertension.

COVID-19 pandemic’s latest variant has pushed FDA to pump brakes again on performing on-site surveillance inspections through at least 19 January. Meanwhile, associate commissioner says Remote Regulatory Assessments “are here to stay.”

Members of Congress in favor of giving FTC authority to impose monetary relief orders against firms linked to false advertising likely were caught off guard when West Virginia Democrat said he wouldn’t vote for legislation with $2.2 trillion for climate change, tax and social programs that President Biden made a primary plank of his Capitol Hill strategy and that the House passed in November.

US Hemp Roundtable submits comments on proposed rule as well as surveys hemp and cannabinoid product market stakeholders “to demonstrate the devastating impact the new rules would have on farmers, retailers and consumers.”

Cannabis-Derived Products Data Acceleration Plan aims to avoid same conclusion already found in FDA's more-than two-year search for information on using cannabis ingredients in supplements, food and beverages and personal care topicals: too little is available to determine safety.